Lupin unveils generic Fosaprepitant injection in US
Mumbai, Baltimore: Pharma major, Lupin Limited, has recently announced the launch of Fosaprepitant for Injection, 150 mg Single-Dose Vial, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck), indicated for adults in combination with other antiemetic agents, for the prevention of:
• Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
• Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Fosaprepitant for Injection, 150 mg Single-Dose Vial, (RLD: Emend) had annual sales of approximately USD 136 million in the U.S. (IQVIA MAT July 2020).
Read also: Lupin unveils generic version of Lipitor Tablets
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
